24 October 2019AmericasSarah Morgan

LSPN 19: choose your IP strategy wisely, warn IP experts

Choosing the right IP strategy is crucial for companies, but constrained budgets and picking the wrong partners are all factors that can steer companies off the correct path.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

LSPN 19: PTAB and ‘languishing’ STRONGER Act on 2020 agenda

22 October 2019 While the next Alice or Mayo is unlikely to be handed down next year, there are many slightly less “revolutionary" developments likely to crop up in 2020, according to Charles Larsen, partner at White & Case.

LSPN 19: AI ‘explosion’ and drug costs in Canada

17 October 2019 Uncertainty surrounding the patentability of artificial intelligence (AI) and changes to patented medicine pricing in Canada were two topics discussed yesterday, October 15 at Life Sciences Patent Network Fall in San Francisco.

More on this story

LSPN 19: PTAB and ‘languishing’ STRONGER Act on 2020 agenda

22 October 2019 While the next Alice or Mayo is unlikely to be handed down next year, there are many slightly less “revolutionary" developments likely to crop up in 2020, according to Charles Larsen, partner at White & Case.

LSPN 19: AI ‘explosion’ and drug costs in Canada

17 October 2019 Uncertainty surrounding the patentability of artificial intelligence (AI) and changes to patented medicine pricing in Canada were two topics discussed yesterday, October 15 at Life Sciences Patent Network Fall in San Francisco.

More on this story

LSPN 19: PTAB and ‘languishing’ STRONGER Act on 2020 agenda

22 October 2019 While the next Alice or Mayo is unlikely to be handed down next year, there are many slightly less “revolutionary" developments likely to crop up in 2020, according to Charles Larsen, partner at White & Case.

LSPN 19: AI ‘explosion’ and drug costs in Canada

17 October 2019 Uncertainty surrounding the patentability of artificial intelligence (AI) and changes to patented medicine pricing in Canada were two topics discussed yesterday, October 15 at Life Sciences Patent Network Fall in San Francisco.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent